Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors

Expanding the US Food and Drug Administration–approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1%–12% and a high fatality rate relative to other...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Guidon, Amanda C, Burton, Leeann B, Chwalisz, Bart K, Hillis, James, Schaller, Teilo H, Amato, Anthony A, Betof Warner, Allison, Brastianos, Priscilla K, Cho, Tracey A, Clardy, Stacey L, Cohen, Justine V, Dietrich, Jorg, Dougan, Michael, Doughty, Christopher T, Dubey, Divyanshu, Gelfand, Jeffrey M, Guptill, Jeffrey T, Johnson, Douglas B, Juel, Vern C, Kadish, Robert, Kolb, Noah, LeBoeuf, Nicole R, Linnoila, Jenny, Mammen, Andrew L, Martinez-Lage, Maria, Mooradian, Meghan J, Naidoo, Jarushka, Neilan, Tomas G, Reardon, David A, Rubin, Krista M, Santomasso, Bianca D, Sullivan, Ryan J, Wang, Nancy, Woodman, Karin, Zubiri, Leyre, Louv, William C, Reynolds, Kerry L
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2021
Matèries:
Position Article and Guidelines
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8291304/
https://ncbi.nlm.nih.gov/pubmed/34281989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002890
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars